* Q2 EBIT SEK -74m (vs. ABGSCe 103m) * EBIT negatively impacted by delay in Pome project timeline * ...
Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the ...
Redeye provides an update following Neola Medical’s Q2 2025 report.
We hosted NoHo Partners' CEO Jarno Suominen for a lunch meeting today in Helsinki.
Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Redeye comments on Active Biotech's second quarter report.
Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q2 2025 report, which w...
Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y, which wa...
* Net acquistions in H2'25 * Buy-backs supportive for the share * 2025e P/CEPS 11x vs.
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the qua...
* Gross margin at 45% (40%) * SaaS supports margins and outlook * Trading at ~11-9x EV/EBITA for '26...
* Q2 NAV in line with ABGSCe * Key highlights: Safe Life transaction and buybacks * Discount still w...
